Zealand Pharma A/S (OTCMKTS:ZLDPF) Earns Neutral Rating from Cantor Fitzgerald

Zealand Pharma A/S (OTCMKTS:ZLDPF)‘s stock had its “neutral” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Friday, Marketbeat reports.

ZLDPF has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Four investment analysts have rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy”.

Zealand Pharma A/S Trading Down 30.7%

OTCMKTS ZLDPF opened at $39.95 on Friday. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $101.29. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2.84 billion, a P/E ratio of 2.92 and a beta of 0.75. The business has a fifty day simple moving average of $64.22 and a 200 day simple moving average of $70.69.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. The firm had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. On average, analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Key Headlines Impacting Zealand Pharma A/S

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait‑and‑see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell‑side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight‑loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight‑loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.